The lowered ARR and revenue guidance for FY26 is a material negative signal, indicating decelerating growth and execution challenges in core subscription expansion. Traders should watch the Q3 earnings call for evidence of Inseyets conversion recovery and new product (Genesis) adoption; the raised EBITDA target suggests cost discipline but does not offset the top-line miss. The CEO transition to a product-focused leader may be a positive long-term catalyst but adds near-term uncertainty.
Price Chart
Executive Summary
Cellebrite reported Q2 2026 revenue of $131.1M (+16% YoY) and GAAP EPS of $0.02, but lowered its full-year ARR guidance to $550M-$560M (14%-16% growth, down from prior expectations) and revenue outlook to $555M-$561M, citing longer sales cycles and slower Inseyets conversions. The company raised its adjusted EBITDA target to $153M-$159M and announced a planned CEO transition from Thomas Hogan to Shiven Ramji. The lowered top-line guidance is the dominant signal, outweighing the EBITDA raise and CEO change, making this a bearish event for the common stock.
Key Facts
- Q2 2026 revenue of $131.1M, up 16% YoY
- Q2 2026 GAAP diluted EPS of $0.02 vs $0.08 YoY
- Q2 2026 Non-GAAP diluted EPS of $0.11 vs $0.12 YoY
- Total ARR of $507.8M, up 21% YoY
- Full-year 2026 ARR guidance lowered to $550M-$560M (14%-16% growth)
- Full-year 2026 revenue guidance lowered to $555M-$561M (17%-18% growth)
- Full-year 2026 adjusted EBITDA target raised to $153M-$159M (~28% margin)
- CEO transition: Shiven Ramji succeeds Thomas E. Hogan effective immediately
- GAAP operating income fell to $6.9M from $14.4M YoY; operating margin 5.3% vs 12.7%
- Free cash flow for trailing twelve months was $144.2M, 28.0% margin
Financial Impact
Revenue guidance cut by ~$20M-$30M at midpoint vs prior expectations; ARR growth decelerating from 21% to 14%-16%
Risk Factors
- Further deceleration in ARR growth if elongated sales cycles persist
- Inseyets conversion shortfall may indicate competitive or product-market fit issues
- New CEO transition could cause execution disruption in the near term
- GAAP operating margin compressed to 5.3% from 12.7% YoY due to rising costs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-088681 |
| Document: ea0301880-6k_cellebrite.htm | 0001213900-26-088681 |
| Document: 0001213900-26-088681-index-headers.html | 0001213900-26-088681 |
| Document: 0001213900-26-088681-index.html | 0001213900-26-088681 |
| Document: 0001213900-26-088681.txt | 0001213900-26-088681 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | SC 13G | $11.44 $11.15 | ▼ −2.58% | ▼ −1.09% | $12.23 (+6.91%) |
Oct 7, 2026 19d ago | 144 | $11.23 $10.83 | ▼ −3.52% | ▼ −2.54% | $12.23 (+8.95%) |
Aug 27, 2026 8w ago | Insider Cluster | $11.99 $11.45 | ▼ −4.50% | ▼ −4.61% | $12.23 (+2.00%) |
Aug 27, 2026 8w ago | Insider Cluster | $11.99 $11.45 | ▲ +4.50% | ▲ +4.61% | $12.23 (−2.00%) |
Aug 25, 2026 8w ago | Insider Cluster | $11.62 $11.62 | · 0.00% | ▲ +0.12% | $12.23 (+5.25%) |
Aug 24, 2026 9w ago | Insider Cluster | $11.29 $11.85 | ▲ +4.96% | ▲ +5.50% | $12.23 (+8.33%) |
Aug 19, 2026 9w ago | 144 | $11.24 $11.62 | ▲ +3.38% | ▲ +3.77% | $12.23 (+8.81%) |
Aug 13, 2026 10w ago | Insider Cluster | $11.14 $11.05 | ▼ −0.81% | ▲ +0.56% | $12.23 (+9.78%) |
Aug 13, 2026 10w ago | 6-K | $11.14 $11.05 | ▼ −0.81% | ▲ +0.56% | $12.23 (+9.78%) |
Aug 13, 2026 10w ago | 6-K | $10.80 $11.31 | ▼ −4.72% | ▼ −6.69% | $12.23 (−13.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers